Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
information fournie par Boursorama CP 27/05/2022 à 08:00
Ajoutez Boursorama à vos sources préférées

Strasbourg, France, May 27, 2022, 8:00 am CEST - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The conference will be held online and in-person in Chicago, IL, USA, from June 3 to 7, 2022.

The abstract reports positive immunogenicity and clinical data generated from the two ongoing Phase I trials in patients with ovarian cancer and HPV-negative head and neck cancer (NCT03839524 and NCT04183166). The detailed data will be presented during a poster session on June 5, 2022, at the ASCO conference.

.../...

Valeurs associées

TRANSGENE
0,8060 EUR Euronext Paris -0,12%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
CAC 40
8 439,2 -0,16%
Pétrole Brent
88,32 -4,00%
BIOPHYTIS
0,08 +1,01%
ATON
0,0198 +16,47%
2CRSI
27,56 +4,16%
Chargement...

Pages les plus populaires

L'offre BoursoBank